First in class.

• Autores: Christine Soares
• Localización: Scientific American, ISSN 0036-8733, Vol. 299, Nº. 3, 2008, págs. 28-30
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The article reports on negative publicity which Pfizer Inc. has received in 2008 in response to its popular smoking cessation drug Chantix. A discussion of adverse medical and psychological events which have been linked to the drug and reported, and of a decision from the U.S. Federal Aviation Administration to ban the drug's use among its pilots, is presented.